These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22987950)

  • 1. Treatment of advanced pancreatic cancer.
    Labianca R; Merelli B; Mosconi S
    Ann Oncol; 2012 Sep; 23 Suppl 10():x139-40. PubMed ID: 22987950
    [No Abstract]   [Full Text] [Related]  

  • 2. New guideline-sanctioned and emerging interventions for pancreatic cancer.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):7-9. PubMed ID: 30807561
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemcitabine in the treatment of metastatic pancreatic cancer.
    Hilbig A; Oettle H
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):511-23. PubMed ID: 18402518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine plus cisplatin in advanced pancreatic cancer.
    McWilliams RR; Alberts SR
    J Clin Oncol; 2007 Mar; 25(9):1142; author reply 1142-3. PubMed ID: 17369580
    [No Abstract]   [Full Text] [Related]  

  • 5. [A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
    Kawasaki H; Kukita K; Mizushima Y; Hirata K
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1239-42. PubMed ID: 18633272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of efficacy of arterial infusion chemotherapy with gemcitabine for four cases of advanced pancreatic cancer].
    Doi K; Ohchi T; Ogata K; Matsuo A; Kudoh K; Ohtao R; Muranaka T
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):2013-5. PubMed ID: 18219883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
    Ohkawa S
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():198-202. PubMed ID: 16457249
    [No Abstract]   [Full Text] [Related]  

  • 8. [A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1].
    Fujimoto C; Maruyama Y; Niina Y; Fujimori N; Sumii T; Funakoshi A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1013-6. PubMed ID: 18633236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Heinemann V
    J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
    [No Abstract]   [Full Text] [Related]  

  • 10. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560
    [No Abstract]   [Full Text] [Related]  

  • 11. [Salvage chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer: survival benefit in selected patients].
    Lee JL; Kim YT
    Korean J Gastroenterol; 2008 Jul; 52(1):59-63. PubMed ID: 19077495
    [No Abstract]   [Full Text] [Related]  

  • 12. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
    Kourie HR; Gharios J; Kattan J
    Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
    [No Abstract]   [Full Text] [Related]  

  • 14. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
    Almhanna K; Kim R
    Oncology (Williston Park); 2008 Sep; 22(10):1176-83; discussion 1190, 1192, 1196. PubMed ID: 18935928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
    El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; Abbruzzese JL
    Invest New Drugs; 2011 Aug; 29(4):694-9. PubMed ID: 20107864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
    Melnik MK; Webb CP; Richardson PJ; Luttenton CR; Campbell AD; Monroe TJ; O'Rourke TJ; Yost KJ; Szczepanek CM; Bassett MR; Truszkowski KJ; Stein P; Van Brocklin MW; Davis AT; Bedolla G; Vande Woude GF; Koo HM
    Mol Cancer Ther; 2010 Aug; 9(8):2423-9. PubMed ID: 20682649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
    Gourd E
    Lancet Oncol; 2018 Feb; 19(2):e81. PubMed ID: 29276021
    [No Abstract]   [Full Text] [Related]  

  • 19. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
    Richards DA; Kuefler PR; Becerra C; Wilfong LS; Gersh RH; Boehm KA; Zhan F; Asmar L; Myrand SP; Hozak RR; Zhao L; Gill JF; Mullaney BP; Obasaju CK; Nicol SJ
    Invest New Drugs; 2011 Feb; 29(1):144-53. PubMed ID: 19714296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How I treat ... An advanced pancreatic cancer].
    Polus M; Jerusalem G; Sautois B; Silvestre RM; Fillet G
    Rev Med Liege; 2002 Mar; 57(3):131-4. PubMed ID: 12014258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.